RNA interference in the clinic: challenges and future directions

By C. Pecot, George A. Calin, R. Coleman, Gabriel Lopez-Berestein, Anil Sood. Nature Reviews. Cancer, 2010

819 citations recorded by the source corpus.

Inherent difficulties with blocking many desirable targets using conventional approaches have prompted many to consider using RNA interference (RNAi) as a therapeutic approach. Although exploitation of RNAi has immense potential as a cancer therapeutic, many physiological obstacles stand in the way of successful and efficient delivery. This Review explores current challenges to the development of synthetic RNAi-based therapies and considers new approaches to circumvent biological barriers, to avoid intolerable side effects and to achieve controlled and sustained release.

Subfields: Cancer Research, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/1471bb7e69f39b6f3a863b3e22d1cc362f4630d6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Leaf Huang
2. Yunching Chen
3. Dong-Yu Gao

Citations in the corpus

• Development of microRNA therapeutics is coming of age (2014, neutral): “However, positively charged lipids have been shown to induce dose-dependent toxicities and an interferon response (Pecot et al , 2011).”
• In vivo delivery of miRNAs for cancer therapy: Challenges and strategies (2014, background): “hinder the development and clinical application of cationic lipid-based delivery system [57,58].”